England and Wales to approve new injectable HIV prevention treatment
The UK is set to approve a new injectable treatment for HIV prevention, known as Cabotegravir (CAB-LA), for use in England and Wales. Unlike traditional PrEP pills, which must be taken daily, CAB-LA is administered as an injection every two months, offering an alternative for those who cannot take o... [More info]
Before the end of the year, 867 government health facilities will start to roll out the two-monthly HIV prevention injection, CAB-LA. The US government’s Aids fund, Pepfar, has donated 231 000 doses over two years to South Africa — 96 000 of the doses will arrive between October and December.
HIV prevention injections have been registered for use in South Africa, but their high price and limited supply means that for the next few years, while awaiting more affordable generics, very few people will be able to get the jabs. In this special briefing, Spotlight looks at the difficult choices facing the country if we want to offer the injection to more people more quickly. The calls we make could have global implications.
South Africa ‘can’t afford’ to pay for new anti-HIV drug, despite cut-price offer | Global development | The Guardian
https://www.theguardian.com/global-development/2023/nov/17/south-africa-hiv-cab-la-cabotegravir-viiv-healthcare
#SouthAfrica
#HIV
#AntiHIVDrug
#Cabotegravir
#CABLA
#Pepfar
#ViiV
#Cipla
machopaphrodite at KillBait
ehwoza
AutisticMumTo3